Immunitybio announces completion of $470 million post-merger financing to fund late-stage cancer clinical trials, phase 3 of covid t-cell universal boost vaccine trial and provides update on bladder cancer bla filing

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing in 2021, with $300 million in new debt financing from nantcapital, llc. with this new financing from immunitybio's founder, executive chairman and global chief scientific and medical officer, dr. patrick soon-shiong, on december 17, 2021, the company is now well positioned to pursue its late-stage clinical
IBRX Ratings Summary
IBRX Quant Ranking